Objective: To compare the regulatory differentiation of antibiotic access in Poland and Ukraine according to the WHO AWaRe classification and to assess its relevance for combating antimicrobial resistance under wartime conditions. Methods: A normative-analytical approach was applied to compare the pharmaceutical legislation of Ukraine and Poland. Data were verified through national public registries (January 2025) and classified according to the Anatomical Therapeutic Chemical Classification System and International Nonproprietary Names under the WHO AWaRe framework. The prescription status of antibiotics – drug, dispensed to the patient on a doctor's prescription (Rp); drugs dispensed with a doctor's prescription for registered use (Rpz); preparations only used in inpatient treatment (Lz); and drugs dispensed without a doctor's prescription (OTC) was identified. The Index of Control over Access to Antibiotics was calculated to quantify the level of regulatory restriction within AWaRe groups. Results: The Polish model aligns with WHO AWaRe principles: Access – four control levels (The ICAA= 0.341), Watch – two (0.259), Reserve – three (0.106). OTC sales are permitted only for furazidin (4.8%, Access). In Ukraine, a single-level prescription system (Rx) operates, with Index of Control over Access to Antibiotics values of 0.049 for Access, 0.150 for Watch, and 0.052 for Reserve. Poland demonstrates a higher control level and compliance with the European Centre for Disease Prevention and Control recommendations (≥ 60% Access group utilization). Conclusion: The Polish antibiotic access system is structured, harmonized with WHO AWaRe and European Union antimicrobial stewardship policies, ensuring a balance between accessibility and control. The Ukrainian Rx/OTC model remains simplified; gradual implementation of a multi-level prescription framework, beginning with the Lz category for Reserve antibiotics, is recommended to strengthen national antimicrobial stewardship policy effectiveness.